GlassScriptPhysician profile
Myra Blankenship
NPI 1760668271
$12,483.80
in general payments reported to CMS, 2019-2025
59 companies · $3,618 in 2025
The $3,618 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,896 · 2022: $1,383 · 2023: $763 · 2024: $824 · 2025: $3,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Education: $216 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,889.69 |
| Education | $215.86 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $829.15 | 2021-2025 | Reblozyl, Opdivo |
| Daiichi Sankyo INC. | $715.13 | 2021-2025 | Enhertu, Datroway |
| Seagen INC. | $679.55 | 2021-2025 | |
| Incyte Corporation | $602.65 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $592.42 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Amgen INC. | $543.82 | 2021-2024 | Evenity |
| Astrazeneca Pharmaceuticals LP | $512.62 | 2021-2025 | Lynparza, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $472.80 | 2022-2025 | |
| Lilly USA, LLC | $465.99 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $452.32 | 2021-2025 | Libtayo |
| Eisai INC. | $445.58 | 2021-2025 | |
| Glaxosmithkline, LLC. | $433.88 | 2021-2025 | Ojjaara |
| Abbvie INC. | $419.92 | 2021-2025 | |
| Celgene Corporation | $370.66 | 2021-2025 | Reblozyl |
| Puma Biotechnology, INC. | $352.32 | 2021-2025 | Nerlynx |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $310.40 | 2021-2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $282.71 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $281.55 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Epizyme, INC. | $280.05 | 2021-2022 | |
| Genzyme Corporation | $265.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $265.27 | 2021-2025 | Ninlaro, Exkivity |
| Genentech USA, INC. | $256.16 | 2021-2025 | Venclexta, Columvi, Lunsumio |
| Pfizer INC. | $199.80 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $193.85 | 2021-2025 | Xpovio |
| Astellas Pharma US INC | $188.18 | 2021-2025 | Padcev, Xtandi, Vyloy |
| Gilead Sciences, INC. | $180.36 | 2021-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $171.29 | 2021-2025 | |
| Iovance Biotherapeutics, INC. | $145.12 | 2025 | Amtagvi |
| Tersera Therapeutics LLC | $128.75 | 2021-2025 | Zoladex, Xermelo |
| Sanofi-Aventis U.S. LLC | $117.48 | 2021-2022 | |
| Novocure INC. | $97.17 | 2021-2025 | Optune Lua (Novottf-200t) |
| Ipsen Biopharmaceuticals, INC | $95.95 | 2021 | |
| Pharmacosmos Therapeutics INC. | $92.24 | 2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.73 | 2021-2025 | Gilotrif |
| Intuitive Surgical, INC. | $82.47 | 2025 | |
| Tactile Systems Technology INC | $81.22 | 2025 | Flexitouch Plus, Nimbl |
| Aveo Pharmaceuticals, INC. | $80.74 | 2021-2025 | |
| Taiho Oncology, INC. | $76.72 | 2021-2025 | |
| Novo Nordisk INC | $71.72 | 2021 | |
| Beone Medicines USA, INC. | $62.94 | 2025 | Tevimbra, Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $53.46 | 2021 | |
| Array Biopharma INC | $50.81 | 2021-2024 | Mektovi, Braftovi |
| Emd Serono, INC. | $45.85 | 2021-2025 | |
| Coherus Oncology, INC. | $45.21 | 2021-2022 | |
| Beigene USA, INC. | $44.30 | 2022-2025 | Tevimbra |
| Rigel Pharmaceuticals, INC. | $38.59 | 2021-2025 | Gavreto, Rezlidhia, Tavalisse |
| Alexion Pharmaceuticals, INC. | $35.29 | 2021 | |
| Sobi, INC | $21.78 | 2025 | |
| Heron Therapeutics, INC. | $20.49 | 2021 | |
| Geron Corporation | $19.32 | 2025 | Rytelo |
| Myovant Sciences INC. | $17.88 | 2021 | |
| Stemline Therapeutics INC. | $16.09 | 2021 | |
| Agios Pharmaceuticals, INC. | $15.28 | 2021 | |
| Adc Therapeutics America, INC. | $14.18 | 2025 | |
| Kyowa Kirin, INC. | $13.49 | 2025 | |
| Dova Pharmaceuticals | $12.72 | 2021 | |
| Servier Pharmaceuticals LLC | $12.32 | 2021 | |
| Clovis Oncology, INC. | $11.59 | 2021 | |
| Myriad Genetic Laboratories, INC. | $10.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Blankenship listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.